1. Home
  2. CELU

as of 12-31-2025 2:39pm EST

$1.07
$0.05
-4.89%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Founded: 2016 Country:
United States
United States
Employees: N/A City: FLORHAM PARK
Market Cap: 50.7M IPO Year: N/A
Target Price: $6.00 AVG Volume (30 days): 88.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.35 EPS Growth: N/A
52 Week Low/High: $1.00 - $4.35 Next Earning Date: 11-14-2025
Revenue: $40,578,000 Revenue Growth: -15.81%
Revenue Growth (this year): -52.97% Revenue Growth (next year): 76.00%

AI-Powered CELU Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 67.32%
67.32%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Celularity Inc. News

CELU Breaking Stock News: Dive into CELU Ticker-Specific Updates for Smart Investing

All CELU News

Share on Social Networks: